Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism.

Persons

Barbara Emily Bierer

Venue / Journal

J Immunol

Date

Tue, 11/01/2005 - 12:00

Additional Journal Information

175(9):5732-43

Authors

Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, Bierer BE, Fowler DH.

Pubmed URL

http://www.ncbi.nlm.nih.gov/pubmed/16237064